-+ 0.00%
-+ 0.00%
-+ 0.00%

ARROWHEAD PHARMACEUTICALS ANNOUNCES ARO-MAPT INTERIM PHASE 1/2A CLINICAL DATA DEMONSTRATING DEEP AND DURABLE TAU REDUCTIONS IN HEALTHY VOLUNTEERS

Reuters·10/14/2026 11:32:01